All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
EHA2026 Congress | Top abstracts: What’s hot in GvHD?
To help navigate the exciting content being presented at the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the GvHD Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in GvHD.
| Oral presentations: Thursday, June 11 | |||
| Abstract | Title | Presenter | Time (CEST) |
| S266 | ABC: An entirely calcineurin and m‑TOR inhibitor-free short duration GvHD prevention regimen | A Samer Al-Homsi | 17:00–17:15 |
| Oral presentations: Saturday, June 13 | |||
| Abstract | Title | Presenter | Time (CEST) |
| LB5009 | GvHD prophylaxis including ATG remains standard of care for HLA-compatible unrelated donor hematopoietic cell transplantation: Results from a large randomized controlled trial comparing ATG and PTCy | Johannes Schetelig | 18:15–18:30 |
| Posters | |||
| Abstract | Title | Presenter | Date and time (CEST) |
| PF1125 | The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory cGvHD | Yibo Wu | Friday, June 12, from 18:45 |
| PF1131 | Immunosuppressive strategy using low-dose ATG combined with anti-CD25 antibody for GvHD prophylaxis in haploidentical hematopoietic stem cell transplantation | Xiaosheng Fang | Friday, June 12, from 18:45 |
| PF1137 | The combination of ruxolitinib and extracorporeal photopheresis is a highly effective second line treatment for chronic graft-versus-host disease | Andrea Varkonyi | Friday, June 12, from 18:45 |
| PF1140 | Exploration of a novel aGvHD prophylaxis regimen based on gecacitinib in the peritransplant period of patients with myelofibrosis: A pilot open-label study | Na Xu | Friday, June 12, from 18:45 |
| PF1151 | Assessments of bone health among patients with chronic graft-versus-host disease receiving axatilimab in the AGAVE-201 trial | Amandeep Salhotra | Friday, June 12, from 18:45 |
| PF1179 | Association between serum biomakers and acute graft-versus- host disease | Heng Liu | Friday, June 12, from 18:45 |
| PS2226 | Real-world use of post-transplant cyclophosphamide for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation: A survey from the CTIWP of EBMT | Shlomo Elias | Saturday, June 13, from 18:45 |
| PS2231 | Belumosudil in pediatric patients with steroid-refractory chronic graft-versus-host disease | Lipeng Liu | Saturday, June 13, from 18:45 |
| PS2243 | Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Updated safety analysis of a randomized phase 2 study | Robert Zeiser | Saturday, June 13, from 18:45 |
| PS2244 | Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease | Yibo Wu | Saturday, June 13, from 18:45 |
| PS2264 | Clinical outcomes and safety of extracorporeal photopheresis alone or combined with ruxolitinib in chronic graft-versus-host disease | Christian Koch | Saturday, June 13, from 18:45 |
| PS2275 | Umbilical cord-derived mesenchymal stem cells: Elevating early efficacy in gastrointestinal acute graft-versus-host disease | Fang Zhou | Saturday, June 13, from 18:45 |
| PS2415 | Torque teno virus: An emerging biomarker associated with adverse prognosis and the risk of graft-versus-host disease in patients undergoing allo-HSCT | Xiujuan Ma | Saturday, June 13, from 18:45 |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
